A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease | Zendy

Stephan R. Vavricka | Zendy; Alain Schoepfer | Zendy; Ekaterina Safroneeva | Zendy; Gerhard Rogler | Zendy; Matthias Schwenkglenks | Zendy; Rita Achermann | Zendy

Open Access

A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease

Author(s) -

Stephan R. Vavricka,

Alain Schoepfer,

Ekaterina Safroneeva,

Gerhard Rogler,

Matthias Schwenkglenks,

Rita Achermann

Publication year - 2013

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1097/mib.0b013e31827febbb

Subject(s) - medicine , ulcerative colitis , inflammatory bowel disease , odds ratio , gastroenterology , medical prescription , crohn's disease , population , cohort , disease , pharmacology , environmental health

In 2007, leading international experts in the field of inflammatory bowel disease (IBD) recommended intravenous (IV) iron supplements over oral (PO) ones because of superior effectiveness and better tolerance. We aimed to determine the percentage of patients with IBD undergoing iron therapy and to assess the dynamics of iron prescription habits (IV versus PO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research